PASSAGE BIO, INC. Operating Lease Right-of-Use Assets
PASSAGE BIO, INC. (PASG) had Operating Lease Right-of-Use Assets of $651.00 thousand as of 2026-03-31, per its S-4 filed 2026-07-21.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-09-03
- 2026-03-31: Operating Lease, Right-of-Use Asset $651.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $10.17M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $13.00M.
- 2025-06-30: Operating Lease, Right-of-Use Asset $13.27M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-03-31 | $651.00K S-4 · filed 2026-07-21 |
| 2025-12-31 | $10.17M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $13.00M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $13.27M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $13.54M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $13.80M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $14.04M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $16.82M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $17.09M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $16.86M 10-K · filed 2025-03-04 |
| 2023-09-30 | $17.05M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $19.41M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $19.59M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $19.72M 10-K · filed 2024-03-04 |
| 2022-09-30 | $19.89M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $20.05M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $20.21M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |